TWI458482B - Ｃ型肝炎病毒抑制劑 - Google Patents

Ｃ型肝炎病毒抑制劑 Download PDF

Info

Publication number
TWI458482B
TWI458482B TW098104731A TW98104731A TWI458482B TW I458482 B TWI458482 B TW I458482B TW 098104731 A TW098104731 A TW 098104731A TW 98104731 A TW98104731 A TW 98104731A TW I458482 B TWI458482 B TW I458482B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
mmol
hcv
independently selected
Prior art date
Application number
TW098104731A
Other languages
English (en)
Chinese (zh)
Other versions
TW200938192A (en
Inventor
卡羅 巴查德
馬柯南 貝雷碼
丹尼爾Ｈ 戴昂
安德魯Ｃ 古德
傑森 古瑞奇
可林Ａ 詹姆斯
瑞可 拉威
歐瑪Ｄ 洛裴茲
阿連 馬特爾
尼可拉斯Ａ 米恩威爾
范恩Ｎ 恩古顏
傑佛瑞 李 洛明
艾德華Ｈ 魯迪格
勞倫斯Ｂ 辛德
丹尼斯Ｒ 聖羅倫
楊福康
大衛Ｒ 蘭利
王剛
勞倫斯Ｇ 哈曼
Original Assignee
必治妥美雅史谷比公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 必治妥美雅史谷比公司 filed Critical 必治妥美雅史谷比公司
Publication of TW200938192A publication Critical patent/TW200938192A/zh
Application granted granted Critical
Publication of TWI458482B publication Critical patent/TWI458482B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW098104731A 2008-02-13 2009-02-13 Ｃ型肝炎病毒抑制劑 TWI458482B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2827708P 2008-02-13 2008-02-13
US12/358,587 US8147818B2 (en) 2008-02-13 2009-01-23 Hepatitis C virus inhibitors

Publications (2)

Publication Number Publication Date
TW200938192A TW200938192A (en) 2009-09-16
TWI458482B true TWI458482B (zh) 2014-11-01

Family

ID=40581591

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098104731A TWI458482B (zh) 2008-02-13 2009-02-13 Ｃ型肝炎病毒抑制劑

Country Status (27)

Country Link
US (1) US8147818B2 (enExample)
EP (1) EP2245027B1 (enExample)
JP (1) JP5455933B2 (enExample)
KR (1) KR101624365B1 (enExample)
CN (1) CN102143959B (enExample)
AR (1) AR070366A1 (enExample)
AT (1) ATE555109T1 (enExample)
AU (1) AU2009214997B2 (enExample)
BR (1) BRPI0908240A2 (enExample)
CA (1) CA2715559A1 (enExample)
CL (1) CL2009000324A1 (enExample)
CO (1) CO6290682A2 (enExample)
CY (1) CY1112999T1 (enExample)
DK (1) DK2245027T3 (enExample)
EA (1) EA018313B1 (enExample)
ES (1) ES2384911T3 (enExample)
HR (1) HRP20120523T1 (enExample)
IL (1) IL207459A (enExample)
MX (1) MX2010008749A (enExample)
NZ (1) NZ587322A (enExample)
PE (1) PE20091381A1 (enExample)
PL (1) PL2245027T3 (enExample)
PT (1) PT2245027E (enExample)
SI (1) SI2245027T1 (enExample)
TW (1) TWI458482B (enExample)
WO (1) WO2009102633A1 (enExample)
ZA (1) ZA201005484B (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8541424B2 (en) * 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
US8242156B2 (en) * 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UY32462A (es) * 2009-02-23 2010-09-30 Arrow Therapeutics Ltd Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
CA2753382C (en) 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5734956B2 (ja) * 2009-04-15 2015-06-17 アッヴィ・インコーポレイテッド 抗ウィルス化合物
AU2010249080A1 (en) 2009-05-12 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
NZ619205A (en) 2009-05-13 2015-04-24 Gilead Pharmasset Llc Antiviral compounds
AU2010253790A1 (en) 2009-05-29 2011-12-15 Merck Sharp & Dohme Corp. Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2435424B1 (en) 2009-05-29 2015-01-21 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
PL2368890T3 (pl) * 2009-06-11 2013-10-31 Abbvie Bahamas Ltd Inhibitory wirusa zapalenia wątroby C
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP2012533569A (ja) 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
NZ597982A (en) 2009-09-04 2013-01-25 Glaxosmithkline Llc CHEMICAL COMPOUNDS for treating Hepatitis C virus
US8927709B2 (en) * 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) * 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031904A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8703938B2 (en) * 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) * 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031934A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20120276047A1 (en) * 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20110137633A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102791687B (zh) * 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
EP2516430B1 (en) * 2009-12-22 2014-11-05 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012008658A (es) 2010-01-25 2012-12-05 Enanta Pharm Inc Inhibidores del virus de la hepatitis c.
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
US8178531B2 (en) * 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
BR112012022311A2 (pt) * 2010-03-04 2016-08-23 Enanta Pharm Inc agentes farmacêuticos de combinação como inibidores da replicação de hcv.
BR112012022125A2 (pt) * 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
JP2013522375A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
AU2011276526A1 (en) 2010-06-28 2013-01-10 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
EA022127B1 (ru) * 2010-08-04 2015-11-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2603080A4 (en) 2010-08-12 2014-01-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
EP2606041A2 (en) 2010-08-17 2013-06-26 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
CA2809261A1 (en) * 2010-08-26 2012-03-01 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis c virus
JP5731004B2 (ja) 2010-10-26 2015-06-10 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤
NZ726475A (en) * 2010-11-17 2018-07-27 Gilead Pharmasset Llc Antiviral compounds
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) * 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
TW201313697A (zh) 2011-07-26 2013-04-01 Vertex Pharma 製備噻吩化合物之方法
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013021337A1 (en) 2011-08-08 2013-02-14 Lupin Limited Antiviral compounds with a fused tricyclic ring
PH12014500312A1 (en) 2011-08-08 2014-03-31 Lupin Ltd Imidazole derivatives as antiviral agents
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
EP2709613B2 (en) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Methods for treating hcv
UA110354C2 (uk) 2011-11-16 2015-12-25 Гайлід Фармассет Елелсі Противірусні сполуки
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2862755A1 (en) 2012-02-10 2013-08-15 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
JP6069492B2 (ja) 2012-04-25 2017-02-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｃ型肝炎ウイルス阻害剤
WO2013163262A1 (en) 2012-04-25 2013-10-31 Theravance, Inc. Piperazine-piperidine compounds as hepatitis c virus inhibitors
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
UA118256C2 (uk) 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Комбінований склад двох противірусних сполук
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
EP3046924A1 (en) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2015184644A1 (zh) * 2014-06-06 2015-12-10 爱博新药研发(上海)有限公司 抑制丙肝病毒的化合物、药物组合物及其应用
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TWI703141B (zh) * 2015-03-12 2020-09-01 大陸商廣東東陽光藥業有限公司 作為丙型肝炎抑制劑的化合物及其在藥物中的應用
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
CA3093130C (en) 2018-04-19 2023-10-17 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
JP7584418B2 (ja) 2018-12-04 2024-11-15 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
KR20240012476A (ko) 2021-05-21 2024-01-29 길리애드 사이언시즈, 인코포레이티드 지카 바이러스 저해제로서의 펜타사이클릭 유도체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006133326A1 (en) * 2005-06-06 2006-12-14 Bristol-Myers Squibb Company Inhibitors of hcv replication

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
EP0679153A4 (en) 1993-01-14 1996-05-15 Magainin Pharma FINALLY MODIFIED AMINO ACIDS AND PEPTIDES.
WO2006093867A1 (en) 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
DK1940786T3 (da) 2005-09-16 2010-11-08 Arrow Therapeutics Ltd Biphenylderivater og deres anvendelse ved behandling af hepatitis C
WO2007058384A1 (en) 2005-11-17 2007-05-24 Osaka University Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
CA2653924A1 (en) 2006-05-30 2007-12-06 Arrow Therapeutics Limited Biphenyl derivatives and their use in treating hepatitis c
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006133326A1 (en) * 2005-06-06 2006-12-14 Bristol-Myers Squibb Company Inhibitors of hcv replication

Also Published As

Publication number Publication date
PE20091381A1 (es) 2009-09-18
JP5455933B2 (ja) 2014-03-26
EA201001273A1 (ru) 2011-08-30
TW200938192A (en) 2009-09-16
AU2009214997B2 (en) 2013-09-26
CO6290682A2 (es) 2011-06-20
BRPI0908240A2 (pt) 2017-10-10
CN102143959B (zh) 2014-10-22
JP2011511840A (ja) 2011-04-14
AR070366A1 (es) 2010-03-31
ES2384911T3 (es) 2012-07-13
KR20100124290A (ko) 2010-11-26
HK1143812A1 (en) 2011-01-14
DK2245027T3 (da) 2012-08-06
CY1112999T1 (el) 2016-04-13
PT2245027E (pt) 2012-07-04
EA018313B1 (ru) 2013-07-30
KR101624365B1 (ko) 2016-05-25
CA2715559A1 (en) 2009-08-20
EP2245027B1 (en) 2012-04-25
WO2009102633A1 (en) 2009-08-20
AU2009214997A1 (en) 2009-08-20
EP2245027A1 (en) 2010-11-03
ATE555109T1 (de) 2012-05-15
CL2009000324A1 (es) 2010-09-21
NZ587322A (en) 2012-04-27
CN102143959A (zh) 2011-08-03
SI2245027T1 (sl) 2012-08-31
US20090202478A1 (en) 2009-08-13
ZA201005484B (en) 2012-01-25
PL2245027T3 (pl) 2012-09-28
IL207459A (en) 2015-06-30
HRP20120523T1 (hr) 2012-07-31
US8147818B2 (en) 2012-04-03
MX2010008749A (es) 2010-08-31
IL207459A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
TWI458482B (zh) Ｃ型肝炎病毒抑制劑
TWI423798B (zh) Ｃ型肝炎病毒抑制劑
TWI487702B (zh) Ｃ型肝炎病毒抑制劑
CN103153986B (zh) 丙型肝炎病毒抑制剂
KR101492672B1 (ko) Ｃ형 간염 바이러스 억제제로서의 이미다졸릴 바이페닐 이미다졸
JP5612612B2 (ja) Ｃ型肝炎ウイルス阻害剤
TWI547480B (zh) Ｃ型肝炎病毒抑制劑
CN102448956B (zh) 丙型肝炎病毒抑制剂
JP5558556B2 (ja) Ｃ型肝炎ウイルス阻害剤
CN102378762B (zh) 丙型肝炎病毒抑制剂
JP5611959B2 (ja) Ｃ型肝炎ウイルス阻害剤
CN102177141B (zh) 作为丙型肝炎病毒抑制剂的联-1h-苯并咪唑
TWI475019B (zh) Ｃ型肝炎病毒抑制劑
CN102712628B (zh) 丙型肝炎病毒抑制剂
CN101998952B (zh) 丙型肝炎病毒抑制剂
TWI400072B (zh) Ｃ型肝炎病毒抑制劑
CN102015692A (zh) 丙型肝炎病毒抑制剂
CN101754966A (zh) 丙型肝炎病毒抑制剂

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees